Skip to content

Qi Diagnostics and NasDaq-listed Avalon GloboCare Signed Agreement to Enter Diabetes Reversal and Weight Management Markets in The U.S. and European Regions

(Hong Kong, 14 April 2023) Qi Diagnostics Limited, a developer of innovative gas nanosensor technology and in vitro breath diagnostic devices, has announced that it has signed a memorandum of understanding (MOU) with Avalon GloboCare Corp. (NASDAQ: ALBT). Under the terms of the agreement, Avalon will become the exclusive distributor for Qi Diagnostics’ KetoAir Breathalyzer device to market in North America, South America, the U.K. and the European Union. KetoAir™ functions as companion diagnostic and monitoring device for ketogenic dietary management and will initially target the diabetes reversal and weight management markets.

Qi Diagnostics is a Hong Kong-based medical device company with expertise in the development and manufacturing of proprietary Volatile Organic Compound (VOC) nanosensor-based in vitro diagnostic and screening devices. Qi Diagnostics has developed KetoAir™, a breathalyzer for ketogenic health management that has been approved by the United States Food and Drug Administration. It enables users to non-invasively measure their ketone levels by simply blowing into the device and provides accurate real-time reading of ketosis status.

Grover Cheung, founder and Chief Executive Officer of Qi Diagnostics Limited, is excited about this new partnership. “We are very honored to cooperate with Avalon GloboCare to bring our Hong Kong developed product to the international market. The ketogenic diet markets in the United States and Europe are not limited to people who need weight management.  Guided ketogenic diet is also applicable to diabetic patients for reversing diabetes which has long been commonly used in the United States and Europe.”  said Grover Cheung. “I hope bringing KetoAir™ to these regions can help local diabetics patients manage their health. I also wish that this concept of reversing diabetes can be brought back to Hong Kong, China and Asia in future to benefit more diabetic patients.”

“We are very excited to partner with Qi Diagnostics to exclusively distribute the KetoAir™ in North America, South America, the U.K. and the EU. Our initial go-to-market strategy will target diabetes reversal and obesity management. Increasing clinical evidence has demonstrated that nutritional ketosis is one of the most effective treatment options for sustainably reversing diabetes and weight management. A proper ketogenic diet has been clinically proven to reduce blood sugar, improve insulin sensitivity, and reduce inflammation,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. 

Qi Diagnostics and Avalon also intend to collaborate to co-develop a breathalyzer device for potential screening and early detection of lung cancer. Joining the expertise and resources

of both parties to accelerate the development of lung cancer breath diagnosis technology.

###

For media enquiries, please contact info@qidiagnostics.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

en_US